Humasis Co

Humasis Co Retained Earnings

The Retained Earnings of Humasis Co (205470.KQ) as of Nov 10, 2026 is 234.26 B KRW. In the previous year, Retained Earnings was 247.89 B KRW — a change of -5.50% (lower).

Retained Earnings

234.26 BKRW

YoY

-5.50%

Last updated:

Retained Earnings of Humasis Co is 2025 234.26 B KRW. Retained Earnings of Humasis Co was 2024 247.89 B KRW. It decreases by -5.50% lower compared to the previous year.

The Humasis Co Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-8.16 B KRW
Jan 1, 2019
-9.24 B KRW
Jan 1, 2020
11.53 B KRW
Jan 1, 2021
162.19 B KRW
Jan 1, 2022
333.95 B KRW
Jan 1, 2023
278.46 B KRW
Jan 1, 2024
247.89 B KRW
Jan 1, 2025
234.26 B KRW
The Humasis Co Retained Earnings history
YEARRetained EarningsYoY
234.26 BKRW-5.50%
247.89 BKRW-10.98%
278.46 BKRW-16.62%
333.95 BKRW+105.90%
162.19 BKRW+1,307.14%
11.53 BKRW-224.74%
-9.24 BKRW+13.21%
-8.16 BKRW+18.28%
-6.90 BKRW-2,859.65%
250.07 MKRW-10.36%
278.96 MKRW+5,516.19%
4.97 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Retained Earnings of Humasis Co is 234.26 B KRW in 2025.

Retained Earnings of Humasis Co changed from 247.89 B KRW to 234.26 B KRW, representing a -5.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co